Stay updated on Pembrolizumab in Lymphoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Lymphoma Clinical Trial page.

Latest updates to the Pembrolizumab in Lymphoma Clinical Trial page
- Check6 days agoChange DetectedPage revision label updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check13 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check34 days agoChange DetectedThe page shows Revision: v3.4.2; the earlier funding-status notice (Revision: v3.4.1) has been removed.SummaryDifference0.4%

- Check41 days agoChange DetectedAdditions include a site-wide funding/operational status notice (NIH Clinical Center is open) and a new Revision: v3.4.1; a prior Revision: v3.4.0 was removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check48 days agoChange DetectedAdded UI/text elements: 'Show glossary', 'Last Update Submitted that Met QC Criteria', 'No FEAR Act Data', and a new revision label 'Revision: v3.4.0'. Removed or renamed older labels: 'Last Update Submitted that met QC Criteria', 'No FEAR Act data', and 'Revision: v3.3.4'.SummaryDifference0.2%

- Check63 days agoChange DetectedAdded Revision: v3.3.4 and removed Revision: v3.3.3 in the Study Documents section. This appears to be a metadata/version update to the protocol/document rather than a change to trial design or results; to avoid alerts for small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check84 days agoChange DetectedAdded a Locations section listing Washington as a study site (Seattle, WA) and removed the prior Washington Locations label and the HHS Vulnerability Disclosure link; page revision updated to v3.3.3.SummaryDifference0.2%

Stay in the know with updates to Pembrolizumab in Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Lymphoma Clinical Trial page.